(3,5-dimethoxymethoxy-4'-acetamide-trans-stilbene) | 823804-72-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (3,5-dimethoxymethoxy-4'-acetamide-trans-stilbene)
• 英文别名: N-[4-[(1E)-2-(3,5-dihydroxyphenyl)ethenyl]phenyl]acetamide；3,5-dihydroxy-4'-acetamido-trans-stilbene；(e)-N-(4-(3,5-dihydroxystyryl)phenyl)acetamide；N-[4-[(E)-2-(3,5-dihydroxyphenyl)ethenyl]phenyl]acetamide
• CAS: 823804-72-4
• 化学式: C₁₆H₁₅NO₃
• 分子量: 269.3
• InChiKey: VDFSSDUOSSQJAG-NSCUHMNNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-{4-[(E)-2-(3,5-dimethoxyphenyl)ethenyl]phenyl}acetamide 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以78%的产率得到(3,5-dimethoxymethoxy-4'-acetamide-trans-stilbene)
  参考文献：
  名称：

  方便快捷地获得白藜芦醇衍生物及其辐射防护活性

  摘要：

  基于芳基硼酸与苯乙烯的钯催化氧化Heck反应，然后以中等至良好的产率脱甲基，可以轻松快速地获得白藜芦醇衍生物。易于合成一系列具有各种官能团的白藜芦醇衍生物。还已经使用大鼠胸腺细胞评估了合成化合物的放射防护活性。结果表明，一些白藜芦醇衍生物有效地保护了胸腺细胞免受辐射诱导的细胞凋亡。

  DOI：

  10.1016/j.bmcl.2016.07.018

文献信息

• COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS
  申请人：The President and Fellows of Harvard College

  公开号：EP3031461A1

  公开（公告）日：2016-06-15

  Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.

  本文提供了调节sirtuin活性或水平的方法和组合物，从而治疗或预防受试者的肥胖或胰岛素抵抗疾病，如糖尿病。示例性方法包括使细胞与sirtuin激活化合物或抑制化合物接触，从而分别增加或减少脂肪积累。
• Formulation and process for modulating wound healing
  申请人：BioMendics, LLC

  公开号：US10426742B2

  公开（公告）日：2019-10-01

  Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I): wherein: L represents a linker selected from —C≡C—, (a tolan), —CH═CH— (a stilbene, preferably trans); or —CRa═CRb— a stilbene derivative; where Ra and Rb are independently H or phenyl optionally substituted with —(R3)p or —(R4)q; R1 to R4 are independent substituents at any available position of the phenyl rings, preferably at 3, 3′, 4, 4′, and/or 5, 5′; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be ≥1. Each R1 to R2 is independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein. The formulation may include a hydrogel formed by the compounds themselves or otherwise and may include salts and/or complexes.

  本发明公开了通过调节自噬促进伤口愈合的方法和化合物。用于调节自噬的制剂包括选自具有一般结构 (I) 的化合物的第一调节化合物 (FAM)： 其中L 代表选自-C≡C-（甲苯）、-CH═CH-（二苯乙烯，最好是反式）或-CRa═CRb-二苯乙烯衍生物的连接体；其中 Ra 和 Rb 独立地是 H 或任选被-(R3)p 或-(R4)q 取代的苯基； R1至R4是独立的取代基，位于苯基环的任何可用位置，优选位于3，3′、4，4′和/或5，5′；m、n、p和q分别独立地为0、1、2或3，代表环的取代基数目，但m或n中至少有一个必须≥1。每个 R1 至 R2 独立地选自本文所述的取代基，包括但不限于羟基、烷氧基、卤代、卤代甲基和苷。制剂还可包括本文所述的辅助自噬调节化合物（AAM）。制剂可包括由化合物本身或以其它方式形成的水凝胶，并可包括盐和/或复合物。
• Compositions and Methods for Selectively Activating Human Sirtuins
  申请人：Howitz Konrad T.

  公开号：US20120172340A1

  公开（公告）日：2012-07-05

  Methods for identifying selective activators of SIRT5 and/or SIRT1 and methods for using these selective activators in the modulation of SIRT5 and/or SIRT1 are provided.
• Formulation and Process for Modulating Wound Healing
  申请人：BioMendics, LLC

  公开号：US20160296477A1

  公开（公告）日：2016-10-13

  Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I): wherein: L represents a linker selected from —C≡C—, (a tolan), —CH═CH— (a stilbene, preferably trans); or —CR a ═CR b — a stilbene derivative; where R a and R b are independently H or phenyl optionally substituted with —(R 3 ) p or —(R 4 ) q ; R 1 to R 4 are independent substituents at any available position of the phenyl rings, preferably at 3, 3′, 4, 4′, and/or 5, 5′; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be ≧1. Each R 1 to R 2 is independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein. The formulation may include a hydrogel formed by the compounds themselves or otherwise and may include salts and/or complexes.
• US7544497B2
  申请人：——

  公开号：US7544497B2

  公开（公告）日：2009-06-09